Purple Innovation, Inc. (PRPL): debt financing — Purple expands Mattress Firm presence to 12,000 slots; secures $20M incremental loan and issues 14.6M warrants

Purple Innovation, Inc.

Expands Mattress Firm slots from ~5,000 to minimum 12,000; expects ~$70M incremental net revenue starting 2026.
Secures $20M incremental term loan (total $100M); issues 6.56M loan warrants at $1.50 strike.
Grants 8.0M warrants to SGI at $1.50; Sherwood gets exclusive assembly rights for certain product lines sold to Mattress Firm.
Warrants expire March 12, 2035; registration rights require S-1 filing by May 30 or June 30, 2025.

item 1.01 item 2.03 item 3.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Purple Innovation, Inc. amended credit facility of initial principal amount of the senior secured term loan facility by $20.0 million with Coliseum Capital Partners, L.P. at same rate as the Existing Loan.

Instrument: credit facility
Principal: initial principal amount of the senior secured term loan facility by $20.0 million
Counterparty: Coliseum Capital Partners, L.P.
Rate: same rate as the Existing Loan
Event: amendment

Exact text from the filing

provides for a commitment increase pursuant to Section 2.18 of the Amended A&R Credit Agreement in the initial principal amount of the senior secured term loan facility by $20.0 million (the “Second Incremental Loan”) from an aggregate principal amount of up to $80.0 million (the “Existing Loan”) to an initial aggregate principal amount of up to $100.0 million

View on SEC.gov

102 debt financings filed in the last 30 days. Browse all debt financings →

Purple Innovation, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-040151

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.